These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32784267)

  • 1. 177Lu-DOTATATE therapy in metastatic/inoperable pheochromocytoma-paraganglioma.
    Jaiswal SK; Sarathi V; Memon SS; Garg R; Malhotra G; Verma P; Shah R; Sehemby MK; Patil VA; Jadhav S; Lila AR; Shah NS; Bandgar TR
    Endocr Connect; 2020 Oct; 9(9):864-873. PubMed ID: 32784267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of peptide receptor radionuclide therapy in patients with advanced pheochromocytoma and paraganglioma: A single-institution experience and review of the literature.
    Tang CYL; Chua WM; Huang HL; Lam WW; Loh LM; Tai D; Ong SYK; Yan SX; Loke KSH; Ng DC; Tham WY
    J Neuroendocrinol; 2023 Dec; 35(12):e13349. PubMed ID: 37937484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials.
    Severi S; Bongiovanni A; Ferrara M; Nicolini S; Di Mauro F; Sansovini M; Lolli I; Tardelli E; Cittanti C; Di Iorio V; Mezzenga E; Scarpi E; Ibrahim T; Paganelli G; Zovato S
    ESMO Open; 2021 Aug; 6(4):100171. PubMed ID: 34139487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
    Zandee WT; Feelders RA; Smit Duijzentkunst DA; Hofland J; Metselaar RM; Oldenburg RA; van Linge A; Kam BLR; Teunissen JJM; Korpershoek E; Hendriks JM; Abusaris H; Slagter C; Franssen GJH; Brabander T; De Herder WW
    Eur J Endocrinol; 2019 Jul; 181(1):45-53. PubMed ID: 31067510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with
    Vyakaranam AR; Crona J; Norlén O; Granberg D; Garske-Román U; Sandström M; Fröss-Baron K; Thiis-Evensen E; Hellman P; Sundin A
    Cancers (Basel); 2019 Jun; 11(7):. PubMed ID: 31261748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of
    Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S
    Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma.
    Kong G; Grozinsky-Glasberg S; Hofman MS; Callahan J; Meirovitz A; Maimon O; Pattison DA; Gross DJ; Hicks RJ
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3278-3287. PubMed ID: 28605448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
    Parghane RV; Talole S; Prabhash K; Basu S
    Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SYMPATHETIC PARAGANGLIOMA: A SINGLE-CENTER EXPERIENCE FROM WESTERN INDIA.
    Jaiswal SK; Sarathi V; Memon SS; Goroshi M; Jadhav S; Prakash G; Dalvi A; Lila AR; Bandgar T; Shah NS
    Endocr Pract; 2019 Mar; 25(3):211-219. PubMed ID: 30913014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide Receptor Radionuclide Therapy as a Novel Treatment for Metastatic and Invasive Phaeochromocytoma and Paraganglioma.
    Mak IYF; Hayes AR; Khoo B; Grossman A
    Neuroendocrinology; 2019; 109(4):287-298. PubMed ID: 30856620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of hitherto unknown brain meningioma detected on
    Parghane RV; Talole S; Basu S
    World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Thapa P; Parghane R; Basu S
    World J Nucl Med; 2017; 16(3):223-228. PubMed ID: 28670182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With
    Huot Daneault A; Desaulniers M; Beauregard JM; Beaulieu A; Arsenault F; April G; Turcotte É; Buteau FA
    Front Endocrinol (Lausanne); 2021; 12():705271. PubMed ID: 34367072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors.
    Zandee WT; Brabander T; Blažević A; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; de Herder WW
    J Clin Endocrinol Metab; 2019 Apr; 104(4):1336-1344. PubMed ID: 30566620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic Neuroendocrine Tumor with Extensive Bone Marrow Involvement at Diagnosis: Evaluation of Response and Hematological Toxicity Profile of PRRT with (177)Lu-DOTATATE.
    Basu S; Ranade R; Thapa P
    World J Nucl Med; 2016; 15(1):38-43. PubMed ID: 26912977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome of "Sandwich" chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease.
    Parghane RV; Ostwal V; Ramaswamy A; Bhandare M; Chaudhari V; Talole S; Shrikhande SV; Basu S
    Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):913-923. PubMed ID: 32876706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of
    Basu S; Parghane RV; Naik C
    World J Nucl Med; 2020; 19(3):205-210. PubMed ID: 33354174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
    Ranade R; Basu S
    J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eruption of Metastatic Paraganglioma After Successful Therapy with
    Wolf KI; Jha A; van Berkel A; Wild D; Janssen I; Millo CM; Janssen MJR; Gonzales MK; Timmers HJKM; Pacak K
    Nucl Med Mol Imaging; 2019 Jun; 53(3):223-230. PubMed ID: 31231443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups.
    Taïeb D; Jha A; Treglia G; Pacak K
    Endocr Relat Cancer; 2019 Nov; 26(11):R627-R652. PubMed ID: 31561209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.